NZ591179A - Glucagon-like-peptide-2 (glp-2) analogues - Google Patents

Glucagon-like-peptide-2 (glp-2) analogues

Info

Publication number
NZ591179A
NZ591179A NZ591179A NZ59117906A NZ591179A NZ 591179 A NZ591179 A NZ 591179A NZ 591179 A NZ591179 A NZ 591179A NZ 59117906 A NZ59117906 A NZ 59117906A NZ 591179 A NZ591179 A NZ 591179A
Authority
NZ
New Zealand
Prior art keywords
glp
analogue
ala
asp
leu
Prior art date
Application number
NZ591179A
Other languages
English (en)
Inventor
Bjarne Due Larsen
Yvette Miata Petersen
Kirsten Ebbehoj
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36649773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ591179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of NZ591179A publication Critical patent/NZ591179A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/22043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
NZ591179A 2005-05-04 2006-05-04 Glucagon-like-peptide-2 (glp-2) analogues NZ591179A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67806605P 2005-05-04 2005-05-04

Publications (1)

Publication Number Publication Date
NZ591179A true NZ591179A (en) 2012-06-29

Family

ID=36649773

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ591178A NZ591178A (en) 2005-05-04 2006-05-04 Glucagon-like-peptide-2 (glp-2) analogues
NZ562943A NZ562943A (en) 2005-05-04 2006-05-04 Glucagon-like-peptide-2 (glp-2) analogues
NZ591179A NZ591179A (en) 2005-05-04 2006-05-04 Glucagon-like-peptide-2 (glp-2) analogues
NZ593050A NZ593050A (en) 2005-05-04 2006-05-04 Glucagon-like-peptide-2 (glp-2) analogues

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NZ591178A NZ591178A (en) 2005-05-04 2006-05-04 Glucagon-like-peptide-2 (glp-2) analogues
NZ562943A NZ562943A (en) 2005-05-04 2006-05-04 Glucagon-like-peptide-2 (glp-2) analogues

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ593050A NZ593050A (en) 2005-05-04 2006-05-04 Glucagon-like-peptide-2 (glp-2) analogues

Country Status (25)

Country Link
US (7) US7563770B2 (ko)
EP (4) EP2295452A1 (ko)
JP (3) JP5405105B2 (ko)
KR (3) KR101200227B1 (ko)
CN (2) CN101171262B (ko)
AT (1) ATE498631T1 (ko)
AU (1) AU2006242998B2 (ko)
BR (1) BRPI0610091B1 (ko)
CA (1) CA2607150C (ko)
CY (1) CY1111411T1 (ko)
DE (1) DE602006020123D1 (ko)
DK (1) DK1877435T4 (ko)
EA (1) EA014184B1 (ko)
ES (1) ES2361095T5 (ko)
HK (1) HK1108898A1 (ko)
IL (3) IL186746A (ko)
MX (1) MX2007013431A (ko)
NO (1) NO345236B1 (ko)
NZ (4) NZ591178A (ko)
PL (1) PL1877435T5 (ko)
PT (1) PT1877435E (ko)
SI (1) SI1877435T2 (ko)
UA (1) UA95235C2 (ko)
WO (1) WO2006117565A2 (ko)
ZA (2) ZA200709384B (ko)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
SI2386310T1 (sl) 2002-08-28 2019-03-29 Dyax Corp. Metode za ohranjanje organov in tkiv
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP2295452A1 (en) 2005-05-04 2011-03-16 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
CA2643693A1 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
BRPI0715113A2 (pt) † 2006-07-26 2013-06-04 Sandoz Ag Sandoz Sa Sandoz Ltd formulaÇço de caspofungina
JP2010502759A (ja) * 2006-09-12 2010-01-28 コスモ・テクノロジーズ・リミテツド タンパク質物質の経口または直腸投与のための医薬組成物
CA2669806C (en) 2006-11-08 2018-10-02 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
KR20090035279A (ko) * 2007-10-05 2009-04-09 경희대학교 산학협력단 위장관 손상 예방 및 치료용 조성물
US20090110713A1 (en) * 2007-10-31 2009-04-30 Florencia Lim Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
CN102307594A (zh) 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
CN101824087A (zh) * 2009-03-05 2010-09-08 连云港恒邦医药科技有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
HUE039605T2 (hu) 2010-01-06 2019-01-28 Dyax Corp Plazma kallikreint kötõ proteinek
CN103314010B (zh) 2010-08-30 2015-03-04 Nps制药股份有限公司 h[Gly2]GLP-2的固相合成
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CN102212127B (zh) * 2011-05-17 2015-02-04 上海景泽生物技术有限公司 胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途
CN102924589B (zh) * 2011-08-11 2016-08-24 中肽生化有限公司 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
ES2687651T3 (es) 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
EA030911B1 (ru) 2012-02-27 2018-10-31 Амуникс Оперейтинг Инк. Композиции конъюгата xten и способы их получения
CA2872315A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
US20150038674A1 (en) * 2013-08-05 2015-02-05 Bayrak Bertan Boran Use of glp-2 analogues in pulmonary diseases for therapeutic purpose
WO2015148790A1 (en) 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US20160067311A1 (en) * 2014-09-10 2016-03-10 Helsinn Healthcare Sa Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
US20170087216A1 (en) * 2015-09-17 2017-03-30 Helsinn Healthcare Sa Therapeutic Uses of Elsiglutide
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN107987170B (zh) * 2016-10-27 2018-12-18 浙江道尔生物科技有限公司 一种用于治疗肠道疾病的融合蛋白
WO2018104559A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2018104558A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CN110099922A (zh) 2016-12-09 2019-08-06 西兰制药公司 Glp-1/glp-2双重激动剂
BR112019010624A2 (pt) 2016-12-09 2019-10-22 Zealand Pharma As agonistas duplos de glp-1/glp-2 acilados e composição
WO2018142363A1 (en) * 2017-02-06 2018-08-09 Orbicular Pharmaceutical Technologies Private Limited Ready to use compositions of glp-2 analogues through self-administrable devices
TWI791539B (zh) * 2017-06-16 2023-02-11 丹麥商西蘭製藥公司 用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
MX2020004453A (es) * 2017-09-28 2020-07-24 Hanmi Pharm Ind Co Ltd Conjugados de accion prolongada de derivados de glp-2.
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628682A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
CA3129576A1 (en) * 2019-02-11 2020-08-20 Opko Biologics Ltd. Long-acting glp-2 analogs
CN110305223B (zh) 2019-06-26 2022-05-13 重庆派金生物科技有限公司 重组串联融合蛋白制备目标多肽的方法
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
EP4144361A4 (en) * 2020-04-03 2024-05-22 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY OR A COMBINATION THEREOF, COMPRISING GLP-2 DERIVATIVES OR A LONG-ACTING CONJUGATE THEREOF
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
CN111560062A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Elisiglutide的制备方法
CN111560061A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Gelpaglutide的制备方法
CN116157413A (zh) 2020-06-09 2023-05-23 维克蒂生物股份有限公司 阿普拉鲁肽的制造、配制和给药
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope Inc AMPK ACTIVATORS
EP4262847A1 (en) 2020-12-16 2023-10-25 Zealand Pharma A/S Use of glp-2 analogues in patients with renal insufficiency
CN115636876A (zh) * 2021-07-20 2023-01-24 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
KR20240055083A (ko) 2021-09-10 2024-04-26 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(glp-2) 아날로그를 포함하는 조성물을 제제화하는 방법
IL313732A (en) 2021-12-23 2024-08-01 Zealand Pharma As Processes for the synthesis of glucagon-like peptide 2 (Galfi-2) analogs
WO2024068933A1 (en) 2022-09-30 2024-04-04 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs)
WO2024156884A1 (en) 2023-01-27 2024-08-02 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs)
CN116751278B (zh) * 2023-06-21 2024-02-13 杭州信海医药科技有限公司 一种Glepaglutide的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
JP2961045B2 (ja) * 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP1231218B1 (en) † 1996-03-01 2008-05-14 Novo Nordisk A/S An appetite-suppressing peptide, its compositions and use
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP0906338B1 (en) * 1996-04-12 2002-11-06 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US20020025933A1 (en) 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
PT929567E (pt) 1996-09-09 2005-07-29 Zealand Pharma As Sintese em fase solida de peptidos
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
WO1998052600A1 (en) † 1997-05-16 1998-11-26 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
CA2319195A1 (en) * 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
WO1999046283A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AU2020501A (en) 1999-12-08 2001-06-18 1149336 Ontario Inc. Chemotherapy treatment
EP1970072A1 (en) 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
US7112567B2 (en) 2001-02-16 2006-09-26 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
WO2004085471A2 (en) * 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
BRPI0414539B8 (pt) * 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
JP5197012B2 (ja) * 2004-11-01 2013-05-15 エヌピーエス ファーマシューティカルズ インコーポレイテッド 大腸連続性を伴う短腸症候群患者の治療
EP2295452A1 (en) 2005-05-04 2011-03-16 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
CA2669806C (en) * 2006-11-08 2018-10-02 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
KR102255479B1 (ko) 2011-05-18 2021-05-24 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약

Also Published As

Publication number Publication date
JP2013189436A (ja) 2013-09-26
BRPI0610091A2 (pt) 2008-12-09
US20120289466A1 (en) 2012-11-15
ATE498631T1 (de) 2011-03-15
JP2016006125A (ja) 2016-01-14
US20170137487A1 (en) 2017-05-18
KR101242951B1 (ko) 2013-03-13
US8263552B2 (en) 2012-09-11
NZ593050A (en) 2012-12-21
IL210668A0 (en) 2011-03-31
ES2361095T5 (es) 2021-11-23
KR20110095397A (ko) 2011-08-24
US20110152186A1 (en) 2011-06-23
KR101200227B1 (ko) 2012-11-13
KR20110093924A (ko) 2011-08-18
JP2008539713A (ja) 2008-11-20
EP2295452A1 (en) 2011-03-16
US7563770B2 (en) 2009-07-21
NO345236B1 (no) 2020-11-16
KR20080015827A (ko) 2008-02-20
EP1877435A2 (en) 2008-01-16
US20070117752A1 (en) 2007-05-24
JP5876434B2 (ja) 2016-03-02
EP1877435B1 (en) 2011-02-16
US9580487B2 (en) 2017-02-28
IL186746A0 (en) 2008-02-09
US7745403B2 (en) 2010-06-29
IL210668A (en) 2013-05-30
US9125882B2 (en) 2015-09-08
AU2006242998A1 (en) 2006-11-09
CN102659938A (zh) 2012-09-12
WO2006117565A3 (en) 2007-01-11
ZA201100753B (en) 2022-12-21
EP1877435B2 (en) 2021-03-17
EP3473646A1 (en) 2019-04-24
EP2295451A1 (en) 2011-03-16
AU2006242998B2 (en) 2012-03-22
JP6272284B2 (ja) 2018-01-31
NZ591178A (en) 2012-06-29
CY1111411T1 (el) 2015-08-05
BRPI0610091B1 (pt) 2021-08-03
US20150368314A1 (en) 2015-12-24
CA2607150C (en) 2014-08-05
SI1877435T1 (sl) 2011-05-31
NZ562943A (en) 2011-03-31
PL1877435T5 (pl) 2021-09-27
ES2361095T3 (es) 2011-06-13
CN101171262B (zh) 2012-06-27
WO2006117565A2 (en) 2006-11-09
MX2007013431A (es) 2008-01-18
EA200702408A1 (ru) 2008-10-30
ZA200709384B (en) 2011-04-28
IL186746A (en) 2012-08-30
PL1877435T3 (pl) 2011-07-29
KR101242795B1 (ko) 2013-03-12
US20110098222A1 (en) 2011-04-28
US20070231308A1 (en) 2007-10-04
DE602006020123D1 (de) 2011-03-31
DK1877435T4 (da) 2021-03-29
CN101171262A (zh) 2008-04-30
SI1877435T2 (sl) 2021-05-31
EA014184B1 (ru) 2010-10-29
IL210669A0 (en) 2011-03-31
CA2607150A1 (en) 2006-11-09
CN102659938B (zh) 2016-01-20
US8163696B2 (en) 2012-04-24
JP5405105B2 (ja) 2014-02-05
HK1108898A1 (en) 2008-05-23
UA95235C2 (en) 2011-07-25
PT1877435E (pt) 2011-05-24
DK1877435T3 (da) 2011-06-06
NO20076043L (no) 2008-02-04
IL210669A (en) 2013-08-29

Similar Documents

Publication Publication Date Title
CA2607150C (en) Glucagon-like-peptide-2 (glp-2) analogues
WO2008056155A1 (en) Selective glucagon-like-peptide-2 (glp-2) analogues
US20210309708A1 (en) Glucagon-like-peptide-2 (glp-2) analogues

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
S881 Correction of error according section 88(1) (mistake in register by reason of an error or omission on the part of the patent office)

Free format text: CORRECTION TO SPECIFICATION (51)

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 MAY 2016 BY CPA GLOBAL

Effective date: 20130322

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2017 BY HENRY HUGHES IP LIMITED

Effective date: 20160205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2018 BY HENRY HUGHES IP LIMITED

Effective date: 20170427

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2019 BY MEWBURN ELLIS LLP

Effective date: 20180222

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2020 BY MEWBURN ELLIS LLP

Effective date: 20190426

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2021 BY MEWBURN ELLIS LLP

Effective date: 20200430

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2022 BY MEWBURN ELLIS LLP

Effective date: 20210430

LAPS Patent lapsed